ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference
June 16 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat at the Raymond James 2021 Human
Health Innovations Conference on Wednesday, June 23 at 10:40 a.m.
ET.
A live audio webcast of the presentation can be accessed through
the Investors section of the Company's website at
www.ChemoCentryx.com. A replay of the webcast will be available on
the Company's website for two weeks following the live
presentation.
About ChemoCentryxChemoCentryx is a
biopharmaceutical company developing new medications for
inflammatory and autoimmune diseases and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally-administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other inflammatory and autoimmune
diseases and in cancer.
Contacts:Susan M.
KanayaExecutive Vice President,Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Lee Roth, Burns McClellan212.213.0006
lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024